Cellular Transplantation Biology, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan.
Anticancer Res. 2013 Dec;33(12):5681-5.
Post-autologous stem cell transplantation (ASCT) consolidation and maintenance therapies in multiple myeloma (MM) have recently been the central focus of studies. However, there have been no reports of Japanese patients with MM treated with post-ASCT consolidation/maintenance therapies.
We retrospectively evaluated eight Japanese patients with newly-diagnosed symptomatic MM who received ASCT after high-dose melphalan, and three to four courses of bortezomib-plus-dexamethasone and two courses of lenalidomide-plus-dexamethasone followed by maintenance lenalidomide for 6-24 months.
Four patients achieved complete response (CR) after ASCT, and five patients (63%) achieved stringent CR after the consolidation and maintenance therapy; two out of these five were in molecular CR. At the median follow-up of 38 months, all patients were alive and only one patient had disease progression following post-ASCT therapy.
Post-ASCT consolidation and maintenance therapy using lenalidomide may be effective in the treatment of Japanese patients with MM.
自体造血干细胞移植（ASCT）后巩固和维持治疗在多发性骨髓瘤（MM）中最近成为研究的重点。然而，目前尚无日本 MM 患者接受 ASCT 后巩固/维持治疗的报告。
我们回顾性评估了 8 例接受大剂量美法仑后 ASCT 的新诊断有症状 MM 日本患者，这些患者接受了硼替佐米联合地塞米松 3 至 4 个疗程，来那度胺联合地塞米松 2 个疗程，随后接受来那度胺维持治疗 6-24 个月。
4 例患者在 ASCT 后达到完全缓解（CR），5 例患者（63%）在巩固和维持治疗后达到严格的 CR；其中 2 例达到分子 CR。在中位随访 38 个月时，所有患者均存活，仅有 1 例患者在 ASCT 后出现疾病进展。
使用来那度胺的 ASCT 后巩固和维持治疗可能对日本 MM 患者有效。
